Skip to main content
Premium Trial:

Request an Annual Quote

Genotype Product Deals Drive 174-Percent Growth in Illumina's Q3 Revenues

NEW YORK (GenomeWeb News) - Illumina yesterday reported a 174-percent increase in total revenue for the third quarter of 2006, as compared with the same period last year.
 
Citing heightened demand for its BeadChip product line, the company reported total revenue of $53.5 million for the quarter ending Oct. 1, compared with $19.5 million in the third quarter of 2005. 
 
Revenues from product sales nearly tripled to $46.9 million from $16.3 million in the prior-year period.
 
The company cited recent genotyping deals with GlaxoSmithKline, Duke University, Massachusetts General Hospital, and Harvard Medical School as examples of demand for its products.
 
Illumina reported net income of $16.2 million for the quarter, including total non-cash stock compensation expense of $3.8 million, compared to a net loss of $1.5 million in the third quarter of 2005.
 
R&D spending rose to $7.7 million from $7 million in the prior-year period.
 
Illumina ended the third quarter with cash and short-term investments worth $169.9 million, of which $44.2 million was in cash and cash equivalents.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.